| Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (NCT03962465) | University of Virginia | 2022-07-22 |
| A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) (NCT05460533) | Memorial Sloan Kettering Cancer Center | 2022-07-12 |
| CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol (NCT05648019) | KK Women's and Children's Hospital | 2022-03-15 |
| Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL (NCT05082519) | Etan Orgel | 2022-03-12 |
| Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies (NCT06220097) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2022-02-01 |
| CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia (NCT06081478) | Beijing Tongren Hospital | 2022-01-18 |
| Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL (NCT04448834) | Dorothy Sipkins, MD, PhD | 2022-01-01 |
| Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL (NCT04156659) | Novartis Pharmaceuticals | 2021-11-30 |
| Natural Killer (NK) Cell Therapy for B-Cell Malignancies (NCT05379647) | Zhejiang University | 2021-11-04 |
| Venetoclax Plus Inotuzumab for B-ALL (NCT05016947) | Dana-Farber Cancer Institute | 2021-09-24 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers (NCT05020678) | Nkarta, Inc. | 2021-08-20 |
| A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (NCT04595162) | Peking University Third Hospital | 2021-03-15 |
| UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL (NCT04544592) | University of Colorado, Denver | 2021-03-10 |
| RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies (NCT04844086) | Eden BioCell Ltd. | 2021-03-02 |
| Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT (NCT04746209) | Medical College of Wisconsin | 2021-02-01 |
| Induced-T Cell Like NK Cells for B Cell Malignancies (NCT04747093) | Nanfang Hospital, Southern Medical University | 2021-01-29 |
| CAR T Cell Therapy Related Cardiovascular Outcomes (NCT05130489) | University College London Hospitals | 2021-01-18 |
| Blinatumomab Bridging Therapy for BALL (NCT04556084) | Michael Burke | 2021-01-01 |
| Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma (NCT05333302) | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | 2020-10-26 |
| Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia (NCT04289220) | Yan'an Affiliated Hospital of Kunming Medical University | 2020-03-15 |
| CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL (NCT05470777) | The First Affiliated Hospital of Soochow University | 2020-01-19 |
| Study of Out of Specification for Tisagenlecleucel (NCT04094311) | Novartis Pharmaceuticals | 2019-11-21 |
| A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (NCT04129099) | Hebei Yanda Ludaopei Hospital | 2019-10-22 |
| Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) (NCT04150497) | Cellectis S.A. | 2019-10-14 |
| Treatment of Hematological Malignancy With Novel CAR-T Cells. (NCT04191941) | Timmune Biotech Inc. | 2019-09-01 |
| Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (NCT03876769) | Novartis Pharmaceuticals | 2019-06-24 |
| Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab (NCT03982992) | Ludwig-Maximilians - University of Munich | 2019-06-01 |
| Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL） (NCT04534634) | The First Affiliated Hospital of Soochow University | 2019-04-01 |
| Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (NCT03666000) | Imugene Limited | 2019-03-11 |
| A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (NCT03825731) | Hebei Yanda Ludaopei Hospital | 2019-01-17 |
| A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (NCT03825718) | Hebei Yanda Ludaopei Hospital | 2019-01-17 |
| CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. (NCT03671460) | Tianjin Mycure Medical Technology Co., Ltd | 2018-09-07 |
| The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL (NCT03509961) | Pediatric Transplantation & Cellular Therapy Consortium | 2018-08-29 |
| CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia (NCT03854994) | Yan'an Affiliated Hospital of Kunming Medical University | 2018-08-01 |
| ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML (NCT03595917) | Marlise Luskin, MD | 2018-07-24 |
| CD19-CAR-T Cells in Patients With R/R B-ALL (NCT03574168) | Bioceltech Therapeutics, Ltd. | 2018-07-20 |
| CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL (NCT03467256) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2018-05-14 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206) | Shenzhen BinDeBio Ltd. | 2018-03-01 |
| Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma (NCT03281551) | Pinze Lifetechnology Co. Ltd. | 2017-10-01 |
| CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (NCT03289455) | Autolus Limited | 2017-06-26 |
| Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk (NCT03000335) | Curewize Health Ltd. | 2016-12-01 |
| PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies (NCT02730312) | Xencor, Inc. | 2016-08-01 |
| Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (NCT02746952) | Institut de Recherches Internationales Servier | 2016-08-01 |
| The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). (NCT02924753) | Henan Cancer Hospital | 2016-07-18 |
| Study of Efficacy and Safety of CTL019 in Adult ALL Patients (NCT02167360) | Abramson Cancer Center at Penn Medicine | 2016-06-01 |
| Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (NCT02435849) | Novartis Pharmaceuticals | 2015-04-08 |
| Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (NCT02228096) | Novartis Pharmaceuticals | 2014-08-14 |
| Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia (NCT01974479) | National University Health System, Singapore | 2013-09-01 |
| Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) (NCT01207388) | Amgen Research (Munich) GmbH | 2010-11-01 |
| Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia (NCT00289562) | BioCryst Pharmaceuticals | 2004-09-01 |